Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 236

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Systemic Glucocorticoid Therapy: a Review of its Metabolic and Cardiovascular Adverse Events

Fardet, Laurence, Fève, Bruno · 2014 · Drugs

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40265-014-0282-9

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 111

  1. Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient’s opinion. Br J Dermatol. 2007;157(1):142–8. · DOI · Paper page
  2. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Health Care Policy and Research (US); 2006 [cited 2012 Jul 24]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21938845 .
  3. Fardet L. Metabolic and cardiovascular adverse events of systemic glucocorticoid therapy. Rev Med Interne. 2013;34(5):303–9. · DOI
  4. Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. Metab Clin Exp. 2011;60(11):1500–10. · DOI · Paper page
  5. Arnaldi G, Scandali VM, Trementino L, Cardinaletti M, Appolloni G, Boscaro M. Pathophysiology of dyslipidemia in Cushing’s syndrome. Neuroendocrinology. 2010;92(Suppl 1):86–90. · DOI · Paper page
  6. Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol. 2007;275(1–2):43–61. · DOI · Paper page
  7. Fève B, Emorine LJ, Briend-Sutren MM, Lasnier F, Strosberg AD, Pairault J. Differential regulation of beta 1- and beta 2-adrenergic receptor protein and mRNA levels by glucocorticoids during 3T3-F442A adipose differentiation. J Biol Chem. 1990;265(27):16343–9. · DOI
  8. Bujalska IJ, Kumar S, Hewison M, Stewart PM. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase. Endocrinology. 1999;140(7):3188–96. · DOI · Paper page
  9. Hauner H, Entenmann G, Wabitsch M, et al. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest. 1989;84(5):1663–70. · DOI · Paper page
  10. Chanson P, Salenave S. Metabolic syndrome in Cushing’s syndrome. Neuroendocrinology. 2010;92(Suppl 1):96–101. · DOI
  11. Christ-Crain M, Kola B, Lolli F, et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing’s syndrome. FASEB J. 2008;22(6):1672–83. · DOI · Paper page
  12. Lee M-J, Gong D-W, Burkey BF, Fried SK. Pathways regulated by glucocorticoids in omental and subcutaneous human adipose tissues: a microarray study. Am J Physiol Endocrinol Metab. 2011;300(3):E571–80. · DOI
  13. Rebuffé-Scrive M, Brönnegard M, Nilsson A, Eldh J, Gustafsson JA, Björntorp P. Steroid hormone receptors in human adipose tissues. J Clin Endocrinol Metab. 1990;71(5):1215–9. · DOI · Paper page
  14. Lindroos J, Husa J, Mitterer G, et al. Human but not mouse adipogenesis is critically dependent on LMO3. Cell Metab. 2013;18(1):62–74. · DOI
  15. Soumano K, Desbiens S, Rabelo R, Bakopanos E, Camirand A, Silva JE. Glucocorticoids inhibit the transcriptional response of the uncoupling protein-1 gene to adrenergic stimulation in a brown adipose cell line. Mol Cell Endocrinol. 2000;165(1–2):7–15. · DOI
  16. Strack AM, Sebastian RJ, Schwartz MW, Dallman MF. Glucocorticoids and insulin: reciprocal signals for energy balance. Am J Physiol. 1995;268(1 Pt 2):R142–9.
  17. Tataranni PA, Larson DE, Snitker S, Young JB, Flatt JP, Ravussin E. Effects of glucocorticoids on energy metabolism and food intake in humans. Am J Physiol. 1996;271(2 Pt 1):E317–25.
  18. Spencer SJ, Tilbrook A. The glucocorticoid contribution to obesity. Stress. 2011;14(3):233–46. · DOI
  19. Dallman MF, la Fleur SE, Pecoraro NC, Gomez F, Houshyar H, Akana SF. Minireview: glucocorticoids–food intake, abdominal obesity, and wealthy nations in 2004. Endocrinology. 2004;145(6):2633–8. · DOI · Paper page
  20. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420–6. · DOI · Paper page
  21. Fardet L, Cabane J, Lebbé C, Morel P, Flahault A. Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. J Am Acad Dermatol. 2007;57(4):604–9. · DOI
  22. Horber FF, Zürcher RM, Herren H, Crivelli MA, Robotti G, Frey FJ. Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-term dialysis. Am J Clin Nutr. 1986;43(5):758–69. · DOI
  23. Schou AJ, Heuck C, Wolthers OD. Differential effects of short-term prednisolone treatment on peripheral and abdominal subcutaneous thickness in children assessed by ultrasound. Steroids. 2003;68(6):525–31. · DOI
  24. Arena C, Morin A-S, Blanchon T, et al. Impact of glucocorticoid-induced adverse events on adherence in patients receiving long-term systemic glucocorticoid therapy. Br J Dermatol. 2010;163(4):832–7. · DOI
  25. Fardet L, Petersen I, Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing’s syndrome: cohort study. BMJ. 2012;345:e4928. · DOI
  26. Fardet L, Antuna-Puente B, Vatier C, et al. Adipokine profile in glucocorticoid-treated patients: baseline plasma leptin level predicts occurrence of lipodystrophy. Clin Endocrinol (Oxf). 2013;78(1):43–51. · DOI
  27. Fardet L, Kettaneh A, Tiev K-P, et al. Digital photography as an operational tool for assessing corticosteroid-induced lipodystrophy. Eur J Intern Med. 2008;19(5):340–4. · DOI
  28. Fardet L, Flahault A, Kettaneh A, Tiev KP, Tolédano C, Cabane J. Natural history of corticosteroid-induced lipodystrophy: a prospective follow-up of 37 patients. Rev Med Interne. 2007;28(12):825–31. · DOI
  29. Geer EB, Shen W, Strohmayer E, Post KD, Freda PU. Body composition and cardiovascular risk markers after remission of Cushing’s disease: a prospective study using whole-body MRI. J Clin Endocrinol Metab. 2012;97(5):1702–11. · DOI
  30. Barahona M-J, Sucunza N, Resmini E, et al. Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing’s syndrome. J Clin Endocrinol Metab. 2009;94(9):3365–71. · DOI · Paper page
  31. Hansen KB, Vilsbøll T, Bagger JI, Holst JJ, Knop FK. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab. 2010;95(7):3309–17. · DOI
  32. Vander Kooi BT, Onuma H, Oeser JK, et al. The glucose-6-phosphatase catalytic subunit gene promoter contains both positive and negative glucocorticoid response elements. Mol Endocrinol. 2005;19(12):3001–22. · DOI
  33. Dirlewanger M, Schneiter PH, Paquot N, Jequier E, Rey V, Tappy L. Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clin Nutr. 2000;19(1):29–34. · DOI
  34. Beaudry JL, Riddell MC. Effects of glucocorticoids and exercise on pancreatic β-cell function and diabetes development. Diabetes Metab Res Rev. 2012;28(7):560–73. · DOI
  35. Gremlich S, Roduit R, Thorens B. Dexamethasone induces posttranslational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic beta cells. Comparison with the effects of fatty acids. J Biol Chem. 1997;272(6):3216–22. · DOI
  36. Borboni P, Porzio O, Magnaterra R, et al. Quantitative analysis of pancreatic glucokinase gene expression in cultured beta cells by competitive polymerase chain reaction. Mol Cell Endocrinol. 1996;117(2):175–81. · DOI
  37. Ullrich S, Berchtold S, Ranta F, et al. Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes. 2005;54(4):1090–9. · DOI · Paper page
  38. Weinstein SP, Wilson CM, Pritsker A, Cushman SW. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metab Clin Exp. 1998;47(1):3–6. · DOI · Paper page
  39. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med. 2002;17(9):717–20. · DOI · Paper page
  40. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236(6):619–32. · DOI · Paper page
  41. Kim SY, Yoo C-G, Lee CT, et al. Incidence and risk factors of steroid-induced diabetes in patients with respiratory disease. J Korean Med Sci. 2011;26(2):264–7. · DOI
  42. Boudreaux JP, McHugh L, Canafax DM, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation. 1987;44(3):376–81. · DOI · Paper page
  43. Depczynski B, Daly B, Campbell LV, Chisholm DJ, Keogh A. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabet Med. 2000;17(1):15–9. · DOI
  44. Friedman EA, Shyh TP, Beyer MM, Manis T, Butt KM. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol. 1985;5(3):196–202. · DOI
  45. Fisher JE, Smith RS, Lagrandeur R, Lorenz RP. Gestational diabetes mellitus in women receiving beta-adrenergics and corticosteroids for threatened preterm delivery. Obstet Gynecol. 1997;90(6):880–3. · DOI
  46. Feldman-Billard S, Lissak B, Kassaei R, Benrabah R, Héron E. Short-term tolerance of pulse methylprednisolone therapy in patients with diabetes mellitus. Ophthalmology. 2005;112(3):511–5. · DOI
  47. Reynolds RM, Labad J, Sears AV, et al. Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh Type 2 Diabetes Study. Eur J Endocrinol. 2012;166(5):861–8. · DOI
  48. Burt MG, Willenberg VM, Petersons CJ, Smith MD, Ahern MJ, Stranks SN. Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: a cross-sectional study. Rheumatology (Oxford). 2012;51(6):1112–9. · DOI
  49. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001–6. · DOI · Paper page
  50. Andrade-Sierra J, Contreras AM, Monteon FJ, et al. Risk factors and incidence of posttransplant diabetes mellitus in Mexican kidney recipients. Arch Med Res. 2006;37(8):961–6. · doi:10.1016/j.arcmed.2006.05.004
  51. Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64(7):979–83. · DOI · Paper page
  52. Bruno A, Cavallo-Perin P, Cassader M, Pagano G. Deflazacort vs prednisone. Effect on blood glucose control in insulin-treated diabetics. Arch Intern Med. 1987;147(4):679–80. · DOI
  53. Pagano G, Lombardi A, Ferraris GM, Imbimbo B, Cavallo Perin P. Acute effect of prednisone and deflazacort on glucose tolerance in prediabetic subjects. Eur J Clin Pharmacol. 1982;22(5):469–71. · DOI
  54. Yates CJ, Fourlanos S, Colman PG, Cohney SJ. Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation. Nephrol Dial Transplant. 2014;29(3):698–705. · DOI
  55. Kasayama S, Tanaka T, Hashimoto K, Koga M, Kawase I. Efficacy of glimepiride for the treatment of diabetes occurring during glucocorticoid therapy. Diabetes Care. 2002;25(12):2359–60. · DOI
  56. Van Raalte DH, van Genugten RE, Linssen MML, Ouwens DM, Diamant M. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care. 2011;34(2):412–7. · DOI
  57. Arner P, Gunnarsson R, Blomdahl S, Groth CG. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care. 1983;6(1):23–5. · DOI · Paper page
  58. Onwubalili JK, Obineche EN. High incidence of post-transplant diabetes mellitus in a single-centre study. Nephrol Dial Transplant. 1992;7(4):346–9. · DOI
  59. Lemke U, Krones-Herzig A, Berriel Diaz M, et al. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metab. 2008;8(3):212–23. · DOI
  60. Fain JN, Cheema P, Tichansky DS, Madan AK. Stimulation of human omental adipose tissue lipolysis by growth hormone plus dexamethasone. Mol Cell Endocrinol. 2008;295(1–2):101–5. · DOI
  61. Paterson JM, Morton NM, Fievet C, et al. Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA. 2004;101(18):7088–93. · DOI · Paper page
  62. Morton NM. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol. 2010;316(2):154–64. · DOI · Paper page
  63. el-Shaboury AH, Hayes TM. Hyperlipidaemia in asthmatic patients receiving long-term steroid therapy. Br Med J. 1973;2(5858):85–6. · DOI
  64. Jefferys DB, Lessof MH, Mattock MB. Corticosteroid treatment, serum lipids and coronary artery disease. Postgrad Med J. 1980;56(657):491–3. · DOI
  65. Choi HK, Seeger JD. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;53(4):528–35. · DOI
  66. Zimmerman J, Fainaru M, Eisenberg S. The effects of prednisone therapy on plasma lipoproteins and apolipoproteins: a prospective study. Metab Clin Exp. 1984;33(6):521–6. · DOI
  67. Brotman DJ, Girod JP, Garcia MJ, et al. Effects of short-term glucocorticoids on cardiovascular biomarkers. J Clin Endocrinol Metab. 2005;90(6):3202–8. · DOI
  68. Ettinger WH, Klinefelter HF, Kwiterovitch PO. Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis. 1987;63(2–3):167–72. · DOI
  69. Kuroki Y, Kaji H, Kawano S, et al. Prospective short-term effects of glucocorticoid treatment on glucose and lipid metabolism in Japanese. Intern Med. 2010;49(10):897–902. · DOI
  70. Greenman Y. Management of dyslipidemia in Cushing’s syndrome. Neuroendocrinology. 2010;92(Suppl 1):91–5. · DOI
  71. Pinheiro CH da J, Sousa Filho WM de, Oliveira Neto J de, et al. Exercise prevents cardiometabolic alterations induced by chronic use of glucocorticoids. Arq Bras Cardiol. 2009;93(4):400–8, 392–400.
  72. Montrella-Waybill M, Clore JN, Schoolwerth AC, Watlington CO. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor. J Clin Endocrinol Metab. 1991;72(5):1060–6. · DOI
  73. Truhan AP, Ahmed AR. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy. 1989;62(5):375–91.
  74. Williamson PM, Kelly JJ, Whitworth JA. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hypertens Suppl. 1996;14(5):S37–41.
  75. Whitworth JA, Gordon D, Andrews J, Scoggins BA. The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens. 1989;7(7):537–49. · DOI
  76. Whitworth JA, Kelly JJ. Evidence that high dose cortisol-induced Na + retention in man is not mediated by the mineralocorticoid receptor. J Endocrinol Invest. 1995;18(7):586–91. · DOI
  77. Goodwin JE, Zhang J, Geller DS. A critical role for vascular smooth muscle in acute glucocorticoid-induced hypertension. J Am Soc Nephrol. 2008;19(7):1291–9. · DOI
  78. Whitworth JA, Schyvens CG, Zhang Y, Mangos GJ, Kelly JJ. Glucocorticoid-induced hypertension: from mouse to man. Clin Exp Pharmacol Physiol. 2001;28(12):993–6. · DOI · Paper page
  79. Mantero F, Boscaro M. Glucocorticoid-dependent hypertension. J Steroid Biochem Mol Biol. 1992;43(5):409–13. · DOI
  80. Peppa M, Krania M, Raptis SA. Hypertension and other morbidities with Cushing’s syndrome associated with corticosteroids: a review. Integr Blood Press Control. 2011;4:7–16. · DOI
  81. Ong SLH, Whitworth JA. How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids. Endocrinol Metab Clin North Am. 2011;40(2):393–407, ix. · DOI
  82. Sato A, Funder JW, Okubo M, Kubota E, Saruta T. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens. 1995;8(8):823–8. · DOI
  83. Panoulas VF, Douglas KMJ, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford). 2008;47(1):72–5. · DOI · Paper page
  84. Zacharieva S, Torbova S, Orbetzova M, et al. Trandolapril in Cushing’s disease: short-term trandolapril treatment in patients with Cushing’s disease and essential hypertension. Methods Find Exp Clin Pharmacol. 1998;20(5):433–8. · DOI
  85. Zacharieva S, Orbetzova M, Natchev E, et al. Losartan in Cushing’s syndrome. Methods Find Exp Clin Pharmacol. 1998;20(2):163–8. · doi:10.1358/mf.1998.20.2.472459
  86. Szczepaniak LS, Victor RG, Orci L, Unger RH. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res. 2007;101(8):759–67. · DOI · Paper page
  87. Trementino L, Arnaldi G, Appolloni G, et al. Coagulopathy in Cushing’s syndrome. Neuroendocrinology. 2010;92(Suppl 1):55–9. · DOI
  88. Ren R, Oakley RH, Cruz-Topete D, Cidlowski JA. Dual role for glucocorticoids in cardiomyocyte hypertrophy and apoptosis. Endocrinology. 2012;153(11):5346–60. · DOI
  89. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141(10):764–70. · DOI · Paper page
  90. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90(8):859–65. · DOI · Paper page
  91. Van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166(9):1016–20. · DOI · Paper page
  92. Varas-Lorenzo C, Rodriguez LAG, Maguire A, Castellsague J, Perez-Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis. 2007;192(2):376–83. · DOI
  93. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FKL, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52(18):1502–17. · DOI · Paper page
  94. Vayssière BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol. 1997;11(9):1245–55. · DOI · Paper page
  95. Belvisi MG, Wicks SL, Battram CH, et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol. 2001;166(3):1975–82. · DOI · Paper page
  96. Schäcke H, Schottelius A, Döcke W-D, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA. 2004;101(1):227–32. · DOI · Paper page
  97. Markham A, Bryson HM. Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1995;50(2):317–33. · DOI
  98. Krogsgaard MR, Lund B, Johnsson B. A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. J Rheumatol. 1995;22(9):1660–2.
  99. Miner JN, Tyree C, Hu J, et al. A nonsteroidal glucocorticoid receptor antagonist. Mol Endocrinol. 2003;17(1):117–27. · DOI
  100. Coghlan MJ, Jacobson PB, Lane B, et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol. 2003;17(5):860–9. · DOI · Paper page
  101. Patel R, Williams-Dautovich J, Cummins CL. Minireview: new molecular mediators of glucocorticoid receptor activity in metabolic tissues. Mol Endocrinol. 2014;28(7):999–1011. · DOI
  102. Yi C-X, Foppen E, Abplanalp W, et al. Glucocorticoid signaling in the arcuate nucleus modulates hepatic insulin sensitivity. Diabetes. 2012;61(2):339–45. · DOI
  103. Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM. Randomized double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet. 1993;342(8877):949–54. · DOI · Paper page
  104. Rupa V, Jacob M, Mathews MS, Seshadri MS. A prospective, randomised, placebo-controlled trial of postoperative oral steroid in allergic fungal sinusitis. Eur Arch Otorhinolaryngol. 2010;267(2):233–8. · DOI
  105. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351(17):1741–51. · DOI · Paper page
  106. Secchi A, Pastore MR, Sergi A, Pontiroli AE, Pozza G. Prednisone administration in recent onset type I diabetes. J Autoimmun. 1990;3(5):593–600. · DOI
  107. Powell-Tuck J, Bown RL, Chambers TJ, Lennard-Jones JE. A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission. Digestion. 1981;22(5):263–70. · doi:10.1159/000198667
  108. Shubin H. Long term (five or more years) administration of corticosteroids in pulmonary diseases. Dis Chest. 1965;48(3):287–90. · DOI
  109. Raúl Ariza-Andraca C, Barile-Fabris LA, Frati-Munari AC, Baltazár-Montufar P. Risk factors for steroid diabetes in rheumatic patients. Arch Med Res. 1998;29(3):259–62.
  110. Ravnborg M, Sørensen PS, Andersson M, et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol. 2010;9(7):672–80. · DOI
  111. Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut. 1975;16(11):876–83. · DOI · Paper page

Cited by

See all 236

Metadata

Authors
Fardet, L., & Fève, B.
Venue
Drugs
Published
2014-09-10
Volume
74
Issue
15
Pages
1731-1745
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W1965283604
Cited by
236
References
25
FWCI
9.34
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systemic Glucocorticoid Therapy: a Review of its Metabolic and Cardiovascular Adverse Events. https://app.cochat.ai/papers/10.1007/s40265-014-0282-9
The paper
Fardet, L., & Fève, B. (2014). Systemic Glucocorticoid Therapy: a Review of its Metabolic and Cardiovascular Adverse Events. Drugs. https://doi.org/10.1007/s40265-014-0282-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.